Pfizer, Glaxo, J&J Grab ASCO Spotlight
New drugs that target genetic weakness in cancer in the spotlight as ASCO previews its closely followed conference.
Mulling Arena Pharma's Future With Obesity Drug on Approval Path
Thoughts and questions following last week's positive FDA panel for Arena's weight-loss drug lorcaserin.
FDA's Review of Arena Pharma's Obesity Drug Sunnier Than Expected
FDA experts will vote Thursday on whether to recommend approval of Arena's lorcaserin for weight loss.
Vertex: Two-Drug Cystic Fibrosis Therapy Improves Lung Function
Vertex plans to start a phase III study soon; if approved, the two-drug therapy could treat half of cystic fibrosis patients worldwide.
Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix
A closer look at Bristol-Myers Squibb's hepatitis C drug BMS-094 raises troubling questions.
Juicy Details From Tang Capital's Lawsuit Against Savient Pharma
Hedge fund rips into Savient management and demands company liquidate remaining assets.
Arena: FDA Adds Obesity Docs to Panel
Getting ready for the May 10 FDA advisory panel reviewing Arena's obesity drug lorcaserin.
Amarin Shares Move Higher on Competing Fish Oil Data
Amarin's prescription fish oil brushes away a challenge from competitor Omthera Pharmaceuticals.
Analysts Get Hooked On Watson After Actavis Drugs Deal
After making the largest drugs deal of 2012, analysts are hooked on Watson Pharmaceuticals.
Watson Pharma Gets Actavis at 'Generics' Price
Watson Pharmaceuticals is buying Actavis for $5.6B in a cheaper than expected deal.